Sharemaestro Newsreel

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise

MediWound Ltd. (MDWD) exceeded Q2 2026 revenue forecasts, reporting $3.1 million against an expected $2.89 million, leading to a 1.87% rise in pre-market shares. The company reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, anticipating stronger performance in the second …

Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb

Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe on U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company also seeks an injunction to prevent infringement litigation related to its …

Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors

Rosalind Advisors Inc. and related parties have reported a 9.6% beneficial ownership stake in Fennec Pharmaceuticals Inc. (FENC), holding 3,321,333 common shares. This ownership includes shares held by Rosalind Master Fund L.P., and involves shared voting and dispositive power among Rosalind Advisors, Steven Salamon, …

Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% beneficial ownership in Silo Pharma, Inc. (SILO) as of June 30, 2026. This ownership, totaling 125,261 shares, is derived entirely from the exercise of warrants and is capped …

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

This funding roundup highlights recent financial activities in the biotech sector, with Silence Therapeutics and AbCellera launching public offerings, and Beyang Therapeutics and Remepy closing oversubscribed Series A financing rounds. Silence Therapeutics priced its IPO at $13.50 per ADS, expecting to raise approximately $175 …

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.

BioNTech has appointed Guido Oelkers, former CEO of Sobi, as its new chief executive, effective by February 1, 2027. This leadership change is a planned transition to steer BioNTech toward a diversified oncology pipeline, moving beyond its primary focus on COVID-19 vaccines. Oelkers' experience …

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is reminding investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) for alleged securities fraud. The lawsuit claims Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, which supposedly failed to demonstrate clinical differentiation. Investors …

Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results Webcast

Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company

Wells Fargo & Company has raised its price target for Definium Therapeutics (NASDAQ:DFTX) to $72.00 from $68.00, maintaining an "overweight" rating and suggesting a potential upside of 68.26%. This comes amid broadly positive analyst sentiment and recent positive Phase 3 clinical trial results for …

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase

Korro Bio, Inc. (KRRO) reported that insider Lynx1 Capital Management LP and Weston Nichols indirectly purchased a total of 6,684 shares of common stock. These purchases occurred on August 6, 2026, at a weighted average price of $11.3998 per share (5,222 shares), and on …

MeiraGTx earnings beat by $2.02, revenue topped estimates

Celcuity earnings loom as breast cancer drug approval fuels optimism

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.1 loss, and revenues of $0.73 million, surpassing estimates by 388.67%. The company's stock has seen a significant gain of 60.7% year-to-date, outperforming the S&P 500, …

Form 8K Cytokinetics Inc For: 13 August By Investing.com

This article from Investing.com reports that Cytokinetics Inc. filed a Form 8K on August 13th. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of …

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Nektar earnings in focus as Phase 3 trial launch raises stakes

Nektar Therapeutics is preparing to report second-quarter results, with analysts anticipating a loss of $2.00 per share on revenues of $10.38 million. The report comes as the company launched two pivotal Phase 3 trials for its lead drug candidate, rezpegaldesleukin, drawing investor attention to …

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Corp. has signed a Material Transfer Agreement (MTA) with PegBio Co., Ltd to evaluate Lexaria's DehydraTECH technology with PegBio's proprietary GLP-1 molecule for the GLP-1 industry. This collaboration aims to enhance the accessibility and effectiveness of PegBio's GLP-1-related drug products, which target …

Eupraxia reports symptom improvements in EoE trial analysis

Eupraxia Pharmaceuticals Inc. announced positive results from an analysis of its RESOLVE study, showing significant symptom improvements in eosinophilic esophagitis (EoE) patients treated with EP-104GI. The analysis revealed a substantial decrease in moderate to severe odynophagia and dysphagia, with severe symptoms dropping to zero …

OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu

Ovid Therapeutics Inc (NASDAQ: OVID) reported strong Q2 2026 results with significant revenue growth, beating EPS expectations, but remains unprofitable and cash-flow-negative. While its Price-to-Sales ratio is lower than its historical median, suggesting potential undervaluation, its GF Score of 48/100 indicates mixed financial health …

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated …

Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush

Wedbush has reiterated an "outperform" rating for Sutro Biopharma (NASDAQ:STRO) with a $60 price target, suggesting a significant upside. This comes despite the company missing its Q2 earnings and revenue estimates. Several other analysts also hold "Buy" or "Outperform" ratings for the stock, with …

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per …

Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00

Benchmark has lowered its price target for Humacyte (NASDAQ:HUMA) to $1.00 from $2.00, while maintaining a "speculative buy" rating, implying a potential 51% upside. This adjustment comes after Humacyte missed Q2 earnings expectations, reporting a loss of $0.16 per share against an estimated $0.11 …

MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics has announced a $150 million private placement financing, selling common stock and pre-funded warrants to institutional and accredited investors. The proceeds will primarily fund the advancement of ML-007C-MA for Alzheimer's disease psychosis and schizophrenia, including ongoing Phase 2 and planned Phase 3 …

Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall

ADC Therapeutics (ADCT) exceeded Q2 2026 earnings and revenue estimates, but its shares fell due to regulatory concerns regarding its ZYNLONTA combination program, LOTIS-5. Despite the stock drop, the company's ZYNLONTA monotherapy sales remained stable, and management expects its cash reserves to last until …

Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp

Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to …

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the United States. This drug is the first and only FDA-approved PROTAC and is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line …

Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall

Abeona Therapeutics reported Q2 2026 net ZEVASKYN revenue of $11.4 million, missing analyst forecasts of $12.24 million, leading to a 10.99% drop in premarket trading. Despite a 31% sequential revenue increase, operational complexities, including manufacturing issues and patient cancellations, impacted recognized sales. The company …

Ultragenyx (RARE): AQR Capital discloses 6.56M-share, 6.66% ownership stake

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a passive ownership stake in Ultragenyx Pharmaceutical Inc. They beneficially own 6,560,809 shares, which constitutes 6.66% of Ultragenyx’s common stock. The filing, a SCHEDULE 13G, indicates shared voting power over 6,398,809 shares …

Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25

Truist Financial has reiterated its Buy rating for UpStream Bio (UPB.US) and maintained its target price at $25. This indicates the firm's continued positive outlook on the company's stock performance.

Silence Therapeutics Plc (SLN) Stock Price | Live Quotes & Charts | NASDAQ

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx Holdings PLC (MGTX) reported Q2 earnings of $1.71 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.39 per share, and revenue of $321.43 million, which also surpassed expectations. Despite the strong quarterly performance, the company holds a Zacks Rank …

Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Halozyme Therapeutics (HALO) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …